Biotech Values

[ThomasS]

Sirna Therapeutics: 100% visual acuity stabilization observed in all patient groups eight weeks after a single dose of Sirna-027 (4.42 )

Co announces the final results from its recently completed Phase 1 trial for Sirna-027, a novel therapeutic for age-related macular degeneration. Single ascending doses of Sirna-027 were safe and well tolerated, and all 26 patients showed visual acuity stabilization eight weeks after a single injection. In addition, at the same time point, five of 26 patients (19%) experienced clinically significant improvement in visual acuity, indicated by an increase of at least three lines on an eye chart.